Online inquiry

IVTScrip™ mRNA-Human APP, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK25541MR)

This product GTTS-WK25541MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the APP protein. This product can be used in Beta cell-related researches.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human APP, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WK25541MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK14836MR IVTScrip™ mRNA-Human alpha-Sarcoglycan, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA alpha-Sarcoglycan
GTTS-WK23864MR IVTScrip™ mRNA-Human ARNTL2, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARNTL2
GTTS-WK21331MR IVTScrip™ mRNA-Human AIF1L, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AIF1L
GTTS-WK16130MR IVTScrip™ mRNA-Human ANKRD50, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANKRD50
GTTS-WK21238MR IVTScrip™ mRNA-Human ANKS3, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ANKS3
GTTS-WK28666MR IVTScrip™ mRNA-Human ARPC1B, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARPC1B
GTTS-WK18535MR IVTScrip™ mRNA-Human ANKRD66, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ANKRD66
GTTS-WK23141MR IVTScrip™ mRNA-Human APP, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA APP
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW